Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Lung Cancer

Free Subscription Articles published in Lancet Retrieve available abstracts of 27 articles: HTML format

Single Articles

March 2021
1. KHO SS, Ho YF, Chan SK, Tie ST, et al
   Mediastinal melioidosis masquerading as malignancy of the lung.
   Lancet. 2021;397:e8.
   PubMed    
   
   
   February 2021
2. SEZER A, Kilickap S, Gumus M, Bondarenko I, et al
   Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial.
   Lancet. 2021;397:592-604.
   PubMed     Abstract available
   
   
   
3. ROSELL R, Gonzalez-Cao M
   Cemiplimab monotherapy in advanced non-squamous and squamous non-small cell lung cancer.
   Lancet. 2021;397:557-559.
   PubMed    
   
   
   January 2021
4. CERESOLI GL, Pasello G
   Immune checkpoint inhibitors in mesothelioma: a turning point.
   Lancet. 2021;397:348-349.
   PubMed    
   
   
   
5. BAAS P, Scherpereel A, Nowak AK, Fujimoto N, et al
   First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.
   Lancet. 2021;397:375-386.
   PubMed     Abstract available
   
   
   August 2020
6. SZTURZ P, Vermorken JB
   Further clinical interpretation and implications of KEYNOTE-048 findings.
   Lancet. 2020;396:379.
   PubMed    
   
   
   
7. MCCAW ZR, Ludmir EB, Kim DH, Wei LJ, et al
   Further clinical interpretation and implications of KEYNOTE-048 findings.
   Lancet. 2020;396:378-379.
   PubMed    
   
   
   
8. REVANNASIDDAIAH S, Devadas SK, Maka VV, Kilara N, et al
   Further clinical interpretation and implications of KEYNOTE-048 findings.
   Lancet. 2020;396:378.
   PubMed    
   
   
   May 2020
9. HARRIS DA, Willis J, Tomann M
   A new era of coal workers' pneumoconiosis: decades in mines may not be required.
   Lancet. 2020;395:e82.
   PubMed    
   
   
   November 2019
10. LUDMIR EB, McCaw ZR, Grossberg AJ, Wei LJ, et al
    Quantifying the benefit of non-small-cell lung cancer immunotherapy.
    Lancet. 2019;394:1904.
    PubMed    
    
    
    
11. MOK TSK, Zhang J, Lopes G
    Quantifying the benefit of non-small-cell lung cancer immunotherapy - Authors' reply.
    Lancet. 2019;394:1904-1905.
    PubMed    
    
    
    
12. THE LANCET
    Lung cancer: some progress, but still a lot more to do.
    Lancet. 2019;394:1880.
    PubMed    
    
    
    October 2019
13. PAZ-ARES L, Dvorkin M, Chen Y, Reinmuth N, et al
    Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
    Lancet. 2019 Oct 4. pii: S0140-6736(19)32222.
    PubMed     Abstract available
    
    
    
14. GOETZE TO
    Immunotherapy: a new era in small-cell lung cancer.
    Lancet. 2019 Oct 4. pii: S0140-6736(19)32235.
    PubMed    
    
    
    September 2019
15. ZHOU M, Wang H, Zeng X, Yin P, et al
    Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.
    Lancet. 2019;394:1145-1158.
    PubMed     Abstract available
    
    
    May 2019
16. LOO BW JR, Diehn M
    SABR-COMET: harbinger of a new cancer treatment paradigm.
    Lancet. 2019;393:2013-2014.
    PubMed    
    
    
    
17. SMIT EF, de Langen AJ
    Pembrolizumab for all PD-L1-positive NSCLC.
    Lancet. 2019;393:1776-1778.
    PubMed    
    
    
    April 2019
18. MOK TSK, Wu YL, Kudaba I, Kowalski DM, et al
    Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
    Lancet. 2019 Apr 4. pii: S0140-6736(18)32409.
    PubMed     Abstract available
    
    
    September 2017
19. BARNETT R
    Lung cancer.
    Lancet. 2017;390:928.
    PubMed    
    
    
    August 2017
20. RIDKER PM, MacFadyen JG, Thuren T, Everett BM, et al
    Effect of interleukin-1beta inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial.
    Lancet. 2017 Aug 25. pii: S0140-6736(17)32247.
    PubMed     Abstract available
    
    
    
21. JENKINS BJ
    Potential efficacy of interleukin-1beta inhibition in lung cancer.
    Lancet. 2017 Aug 25. pii: S0140-6736(17)32289.
    PubMed    
    
    
    May 2017
22. ROSS RJ, Mann NC
    Synchronous distal phalangeal metastases from primary non-small-cell lung cancer.
    Lancet. 2017 May 25. pii: S0140-6736(17)31288.
    PubMed    
    
    
    
23. HIDA T, Nokihara H, Kondo M, Kim YH, et al
    Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.
    Lancet. 2017 May 10. pii: S0140-6736(17)30565.
    PubMed     Abstract available
    
    
    
24. GAINOR JF, Shaw AT
    J-ALEX: alectinib versus crizotinib in ALK-positive lung cancer.
    Lancet. 2017 May 10. pii: S0140-6736(17)31074.
    PubMed    
    
    
    April 2017
25. LANGLEY RE, Nankivell M, Barton R, Faivre-Finn C, et al
    Whole brain radiotherapy for non-small cell lung cancer - Authors' reply.
    Lancet. 2017;389:1395-1396.
    PubMed    
    
    
    
26. ZHU J, Kang M, Fan X
    Whole brain radiotherapy for non-small cell lung cancer.
    Lancet. 2017;389:1395.
    PubMed    
    
    
    
27. CAGNEY DN, Alexander BM, Aizer AA
    Whole brain radiotherapy for non-small cell lung cancer.
    Lancet. 2017;389:1394-1395.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: